Goldman Sachs Maintains Buy on Humana, Lowers Price Target to $450
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Nathan Rich has maintained a Buy rating on Humana (NYSE:HUM) but has reduced the price target from $515 to $450.

January 26, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Humana but lowers the price target from $515 to $450.
While the reduction in price target could suggest a more conservative outlook on Humana's future stock performance, the maintenance of a Buy rating indicates that Goldman Sachs still sees positive potential in the stock. The impact is likely neutral in the short term as the lowered price target may balance out the positive sentiment of the Buy rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100